Targeting microbubbles

Patent metadata

Field	Value
Publication number	US-11224655-B2
Application number	US-201916431605-A
Country	US
Kind code	B2
Filing date	Jun 4, 2019
Priority date	Aug 24, 2011
Publication date	Jan 18, 2022
Grant date	Jan 18, 2022

Abstract

This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment.

First claim

What is claimed is:

1. A targeting microbubble comprising a compound of formula (I) or formula (II):

2. The targeting microbubble of claim 1 wherein the PEG has a molecular weight of less than 10,000 Daltons.

3. The targeting microbubble of claim 1 wherein the PEG has a molecular weight of less than 5,000 Daltons.

4. The targeting microbubble of claim 1 wherein the PEG has a molecular weight of less than 1,000 Daltons.

5. The targeting microbubble of claim 1 , wherein the PEG is a polymer of 1-30 repeat units, wherein each of the repeat units is an ethylene glycol monomer.

6. The targeting microbubble of claim 1 , further comprising a compound selected from the group consisting of:

7. The targeting microbubble of claim 1 , further comprising a core containing a fluid having a normal boiling point less than 30° C.

8. The targeting microbubble of claim 7 , wherein the fluid is air, CO 2 , a fluorinated or perfluorinated C 1-6 hydrocarbon, or a combination thereof.

9. The targeting microbubble of claim 8 , wherein the fluid is octafluoropropane or dodecafluoropentane.

10. A pharmaceutical composition comprising a plurality of the targeting microbubbles of claim 1 .

11. The pharmaceutical composition of claim 10 , further comprising a physiological fluid.

12. The pharmaceutical composition of claim 10 , further comprising water.

13. The pharmaceutical composition of claim 10 , contained in a vial.

14. The pharmaceutical composition of claim 13 , wherein the vial further contains a fluid having a normal boiling point less than 30° C.

15. The pharmaceutical composition of claim 14 , wherein the fluid is air, CO 2 , a fluorinated or perfluorinated C 1-6 hydrocarbon, or a combination thereof.

16. The pharmaceutical composition of claim 15 , wherein the fluid is a fluorinated hydrocarbon selected from perfluoropropane and perfluoropentane.

17. The pharmaceutical composition of claim 10 , wherein the plurality of targeting microbubbles has an average diameter in the range of 1 micron to 10 microns.

Assignees

• California Inst Of Techn
• Univ California

Inventors

• Grubbs Robert H
• Stoller Marshall Leedy
• Chung Hoyong
• Fitzgerald Alissa M
• Kenny Thomas W
• Thomas Renee M

Classifications

• A61K41/0033 Primary

  Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds (ultrasound therapy per se A61N7/00) · CPC title

• A61K47/6911

  the form being a liposome · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K47/50 Primary

  the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title